Nona Biosciences, a US-based global company involved in technology innovation and antibody discovery and development solutions, announced on Monday that it has signed a strategic collaboration with China-based GeneQuantum Healthcare to progress towards the early discovery of next-generation bioconjugates.

According to the terms of the partnership, Nona Biosciences is to integrate GeneQuantum's exclusive and innovative iLDC (intelligent Ligase-dependent Conjugation) and iGDC (intelligent Glycotransferase-dependent conjugation) platforms, with Nona Biosciences' Harbour Mice platform and technologies, to further improve technology platform capabilities, providing global partners with a one-stop solution for the early discovery of next-generation bioconjugates.

Jingsong Wang, MD, PhD, Nona Biosciences chairman, said: "Leveraging our cutting-edge antibody technologies and extensive experience in antibody research and development, Nona is committed to providing innovative, diverse and customised solutions for preclinical drug development. These efforts have garnered widespread recognition and appreciation from our partners. We look forward to collaborating with GeneQuantum Healthcare to continuously enhance the capabilities of innovative bioconjugate drug research and development, empowering global partners to advance their ADC drug R&D initiatives."